- Pacgen Biopharmaceuticals In-Licenses Compounds for Oral Diseases from Demegen
Pacgen Biopharmaceuticals In-Licenses Compounds for Oral Diseases from Demegen
Vancouver, B.C., Canada, March 22, 2005 – Pacgen Biopharmaceuticals Corporation (“Pacgen”), an international biotechnology company specializing in the development of innovative peptide therapeutics for the prevention and treatment of infectious diseases and immune system regulations, announced today it has in-licensed certain peptides for prescription and over-the-counter pharmaceutical products to treat oral diseases from Demegen, Inc (“Demegen”).
Pacgen's initial focus will be on the treatment for oral candidiasis, for which Demegen already has an approved IND. This condition is an AIDS-defining opportunistic illness that is highly prevalent in HIV-infected individuals. Other immunocompromised individuals, including cancer patients receiving chemotherapy, are also susceptible to oral fungal infections. The disease causes pain, inability to eat, and increased risk of additional infection. Oral candidiasis outbreaks often recur and maintenance therapy may be needed.
David J. Cheng, Ph.D., President and CEO of Pacgen, said: "While Pacgen already has a number of antimicrobial peptides in its pipeline, we are impressed with the clinical development achieved thus far by Demegen, we believe we can get to the market faster by collaborating with Demegen."
Pacgen Biopharmaceuticals Corporation is an international biotechnology company specializing in the development of innovative peptide therapeutics for the prevention and treatment of infectious diseases and immune system regulations where current therapies are inadequate or ineffective. Pacgen's goal is to advance its product candidates into the regulatory approval process and to commercialize its novel peptide technologies through collaborations and corporate partnerships. Pacgen is headquartered in Vancouver, British Columbia, Canada with Research and Development facilities at the National Tsing Hua University in Hsinchu, Taiwan. For additional information, please visit www.pacgenbiopharm.com.
Demegen develops novel and natural peptides for the treatment of bacterial and fungal infections. Demegen operates primarily with strategic partners and development efforts are underway for a number of dermatological, ophthalmic, cosmetic and agricultural applications. Other products to be developed include a treatment for cystic fibrosis infections. For additional information, please visit www.demegen.com.